Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Weak
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Website
N/ATelephone
61.3.9087.1598
Address
Level 4 100 Albert Road South Melbourne, Victoria (VIC) 3205
Description
Lumos Diagnostics Holdings Ltd. engages in the development and manufacture of point-of-care diagnostics solutions to help healthcare professionals more accurately diagnose and manage medical conditions. It manages the provision of diagnostics goods and services. It operates through the United States and Australia geographical segments. The company was founded in 2015 and is headquartered in South Melbourne, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.03 - 0.12
Trade Value (12mth)
AU$152,985.00
1 week
19.05%
1 month
78.57%
YTD
-33.33%
1 year
-25.37%
All time high
1.39
EPS 3 yr Growth
-31.600%
EBITDA Margin
-61.70%
Operating Cashflow
-$14m
Free Cash Flow Return
-47.00%
ROIC
-43.70%
Interest Coverage
-2.70
Quick Ratio
0.60
Shares on Issue (Fully Dilluted)
444m
HALO Sector
Healthcare
Next Company Report Date
20-Aug-24
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
11 July 24 |
Notification of cessation of securities - LDX
×
Notification of cessation of securities - LDX |
09 July 24 |
Lumos Expands Henry Schein FebriDx Distribution Partnership
×
Lumos Expands Henry Schein FebriDx Distribution Partnership |
04 July 24 |
Lumos Expands Distribution for FebriDx in AUS and NZ
×
Lumos Expands Distribution for FebriDx in AUS and NZ |
19 June 24 |
Lumos Receives US$400k Phase 1 Milestone from Hologic
×
Lumos Receives US$400k Phase 1 Milestone from Hologic |
13 June 24 |
Change of Director's Interest Notice - SL
×
Change of Director's Interest Notice - SL |
13 June 24 |
Change of Director's Interest Notice - CR
×
Change of Director's Interest Notice - CR |
04 June 24 |
Lumos Receives Second US$5 million Hologic IP Payment
×
Lumos Receives Second US$5 million Hologic IP Payment |
28 May 24 |
March 2024 Appendix 4C - Correction
×
March 2024 Appendix 4C - Correction |
06 May 24 |
Lumos Achieves Key Phase 1 Milestone in Hologic Agreement
×
Lumos Achieves Key Phase 1 Milestone in Hologic Agreement |
02 May 24 |
Lumos quarterly update video interview with CEO, Doug Ward
×
Lumos quarterly update video interview with CEO, Doug Ward |
01 May 24 |
Notification regarding unquoted securities - LDX
×
Notification regarding unquoted securities - LDX |
23 April 24 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
08 April 24 |
Lumos announces positive FebriDx paediatric study results
×
Lumos announces positive FebriDx paediatric study results |
02 April 24 |
Section 708A Cleansing Statement
×
Section 708A Cleansing Statement |
02 April 24 |
Application for quotation of securities - LDX
×
Application for quotation of securities - LDX |
02 April 24 |
Change in substantial holding
×
Change in substantial holding |
29 February 24 |
Change in substantial holding
×
Change in substantial holding |
28 February 24 |
Appendix 4D and Half Year Report
×
Appendix 4D and Half Year Report |
28 February 24 |
Half Year Results Investor Presentation
×
Half Year Results Investor Presentation |
23 February 24 |
1H FY24 Results Investor Briefing Invitation
×
1H FY24 Results Investor Briefing Invitation |
14 February 24 |
Change in substantial holding
×
Change in substantial holding |
12 February 24 |
Lumos Appoints Henry Schein as US Distributor for FebriDx
×
Lumos Appoints Henry Schein as US Distributor for FebriDx |
05 February 24 |
Lumos Investor Roadshow Presentation
×
Lumos Investor Roadshow Presentation |
31 January 24 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
31 January 24 |
Investor Information Sessions
×
Investor Information Sessions |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.